NEWSLETTER: MEMOTEXT NOTES
Please select an issue.
Volume 4 | Issue Two
Early recognition of diabetes complications
Volume 4 | Issue One
Patient Adherence Solutions
Volume 3 | Issue Five
8th Annual CBI Patient Compliance Adherence and Persistency Summit
Volume 3 | Issue Four
MEMOTEXT & John Hopkins University's Wilmer Eye Institute to use MEMOTEXT technology. Launch of MEMOTEXT Adherence Innovations Blog.
Volume 3 | Issue Three
MEMOTEXT & Trillium Health study the effects of Voice and SMS reminders on the treatment and monitoring of patients with Type II diabetes.
Volume 3 | Issue Two
MEMOTEXT & Biogen Idec Canada Announce Ground-Breaking Partnership to help patients with Multiple Sclerosis.
Volume 3 | Issue One
Synapse Group of USA and Canada provides scientific communications and strategic direction to MEMOTEXT moving towards higher standards of excellence in interactive health communications.
Volume 2 | Issue Five
There is no Pill for Non-Adherence: Though dangerously wide in scope and scale, medication non-compliance issues do not yet appear to be top priority for health organizations and stakeholders.
Volume 2 | Issue Four
Telephone-Linked Care Highly Effective at Modifying Health Behavior: Journal of Medical Systems Summary
Volume 1 | Issue Three
In a recent discussion with Meena Bhogal, Sr. Product Manager, Contraceptive Portfolio, Organon Canada Ltd., Schering Plough, we asked how the RemindMeToday program is doing and whether MEMOTEXT has delivered on its promises.
Volume 1 | Issue Two
As part of its expanded personalized adherence solution, MEMOTEXT announces the release of MemotextPRO, a telephone-based Patient Reported Outcomes (PRO) initiative. MemotextPRO uses Speech-to-Text technology with professional transcription validation. RemindMeToday.ca medication adherence program achieves 91% retention.
Volume 1 | Issue One
Organon Canada and MEMOTEXT launch the RemindMeToday.ca program targeted at users of the Linessa and NuvaRing contraceptive brands.